On August 24, Jincheng Pharm, a listed company on the Shenzhen Stock Exchange, stated on an investor Q&A platform that they have the capability to export their synthesized nicotine and possess the necessary qualifications for export. The nicotine project has a production capacity of 200 tons per year and is currently undergoing technical upgrades.
In addition, the company also expressed strong optimism about the e-cigarette industry. On one hand, the company plans to expand its nicotine industry horizontally by utilizing its nicotine extraction platform and expanding its spice products. On the other hand, the company will actively seek opportunities to expand downstream, fully leveraging the value advantages of its upstream nicotine industry to become a leading player in the nicotine industry. Furthermore, in 2023, the company's wholly-owned subsidiary, Jincheng Pharmaceuticals, obtained new export qualifications for nicotine used in e-cigarettes, and its production scale has been further expanded. This development is significant as it allows the company to expand its domestic and international markets and serve downstream customers.
At the same time, when asked if they supply goods to Skoal, the company stated that its clients are downstream e-cigarette liquid businesses, not Skoal, which is not an e-liquid manufacturer.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
